Below is a figure showing possible trajectories to maximum resistance to cefotaxime. Numbers indicate cefotaxime resistance in micrograms per ml. What is the most likely pathway to max resistance?a. G238S→ g4205a →A42G→M182T→E104Kb. G238S→ A42G →E406F→M182T→g4205ac. E104K→A42G→G238S→M182T→g4205ad. G238S→E104K→A42G→M182T→g4205a Wild type0.09E104KG238S--+--0.13----+1.41A42GG238S----E104KA42G-++--1.41--+-+36222.6G238SA42G32.0A42Gg4205aA42G-++-+-+--+ M182T -+-++2050g4205a++--+362---++ E104T --+++362362+--++362M182TE104KA42GE104Kg4205aE104K-++++ 94205a2900+++-+1650- ++++2050M182TA42G+++++Max. resistanceallele4100First mutation Second mutation Third mutation Fourth mutation Fifth mutation

Antibiotic dosing regimes could be tailored to enhance the efficacy of the drugs by being able to…

Wild type 0.09 E104K G238S --+-- 0.13 1.41 A42G G238S ‒‒‒ E104K A42G -++-- 1.41 --+-+ 362 G238S A42G 32.0 A42G g4205a A42G --++ E104T -++-+ -+--+ M182T -+-++ 22.6 g4205a 2050 ++--+ 362 362 --+++ 362 +++ 362 M182T E104K A42G E104K g4205a E104K -++++ 94205a 2900 +++-+ 1650 ++++ 2050 M182T A42G +++++ Max. resistance allele 4100 First mutation Second mutation Third mutation Fourth mutation Fifth mutation

Wild type 0.09 E104K G238S --+-- 0.13 1.41 A42G G238S ‒‒‒ E104K A42G -++-- 1.41 --+-+ 362 G238S A42G 32.0 A42G g4205a A42G --++ E104T -++-+ -+--+ M182T -+-++ 22.6 g4205a 2050 ++--+ 362 362 --+++ 362 +++ 362 M182T E104K A42G E104K g4205a E104K -++++ 94205a 2900 +++-+ 1650 ++++ 2050 M182T A42G +++++ Max. resistance allele 4100 First mutation Second mutation Third mutation Fourth mutation Fifth mutation

Basic Clinical Laboratory Techniques 6E

6th Edition

ISBN:9781133893943

Author:ESTRIDGE

Publisher:ESTRIDGE

Chapter2: Basic Hematology

Section2.3: Microhematocrit

Problem 4RQ

See similar textbooks

Similar questions

HindII --- 5' GTC - GAC 3', HaeIII --- 5' CC - GG 3', EcoRI --- 5' G - AATTC 3' and BamI --- 5' CCTAG - G 3' 5' AGAATTCTTACGCCGGACGTACCTAGGTTTAGTCGACTC CGCCGCCCCTAGGGTCATCA 3' 3' TCTTAAGAATGCGGCCTGCATGGATCCAAATCAGCTGAGGCGGCGGGGATCCCAGTAGT 5' Number of pieces of DNA , and blunt end fragment (s), and sticky end fragment(s)
Rh-hr Kell Duffy Xg Results D C E с Kp Kp Js Js Fy Fy Xg AHG 0.2 M DTT + + + 0 + + 2+ 2+ + 0 0 0 0 + 0 + 0 0 0 0 + Neg Neg 0 0 + 0 + + 0 + 0 0 + +2+ Neg +2+ 2+ + + + + 0 + 0 + 0 0 + + 0 + + 0 + 0 + 0 + 0 +2+ 24 + 0 0 0 0 + 0 + 0 0 + + 0 Neg Neg ID4 0 + + 0 0 0 + 0 + 0 + +2+ 2+ Neg Neg ID5 0 0 + 0 0 + 0 + + 0 + 0 + + ID6 0 0 + 0 + + 0 0 0 0 + + + 0 + 0 2+ Neg ID7 0 0 + 0 0 + 0 0 0 + 0 0 0 0 + 0 0 + + Neg Neg ID8 + 0 + + 0 0 + 0 + 0 0 + 0 0 + 0 + + 0 + + Neg Neg ID9 0 0 + 0 0 0 + 0 0 + + 0 0 0 + 0 + + + 0 Neg Neg ID10 000 + 0 0 + + + 0 0 0 + 0 + + 0 + 0 + 0 Neg Neg ID11 000 + 00+ 0+ 0 0 + 0 + 0 + 0 + 0 0 + +Neg Neg AC Neg AC, auto control; SC, screening cells; ID, identification panel; Neg. Negative reaction Note: SC1 to SC3 are screening cells, ID1 to ID11 are panel cells. All screening and panel cells have negative results with the IS phase and Thermo Phase. 1. What is the result of the Antibody Screening test? 2. Which of the following panel cells contain only the Js" antigen? 3.…
Q:-What is a xaxim?
1 10 20 30 40 50 60 70 -I---- 5' АTCGGTCТCGGCTACTACАТАAАСGCGCGCATATATCGAТАТСТАGСТАGСТАТCGGTCTAGGCTACTАC 3' TAGCCAGAGCCGATGATGTATTTGCGCGCGTATATAGCTATAGATCGATCGATAGCCAGATCCGATGATG I--------I--- --I--- --I------ --I--- -I---------I Promoter 80 90 100 110 120 130 140 -I---- 5' CAGGTATсGGTCTGATCTAССТAGCTTCTтсттстстстстсссссGCGGGGGCTGTACTATСATGCGTCG 3' GTCCATAGCCAGACTAGATCGATCGAAGAGAAGAGAGAGAGGGGGCGCCCCCGACATGATAGTACGCAGC -I- -I------- -I--- -I---------I RBS 150 160 170 180 190 200 210 -----I--- ---I-- ------I- ---I---------I---- -I---------I 5' тстCGGCTАСТАCGTAAACGCGCGCATATAтCGATATCTAGCТAGСТАТСGGTстCGGCTACTAсGTAAA 3' AGAGCCGATGATGCATTTGCGCGCGTATATAGCTATAGATCGATCGATAGCCAGAGCCGATGATGCATTT 220 230 240 250 --I----- ---I-- ------I--- -I 5' CCCTATTAGCATGGGTCATATTTGTGTCTGCTTGTTGGGT 3' GGGATAATCGTACCCAGTAGAAACACAGACGAAGAACCCA a. What are the nucleotides of the MRNA from gene Z? b. What are the amino acids encoded by gene Z? ( Vate V
Based on the image below, select the correct statement. Complex II QH₂ Q- 10 2 HO 2 HO Fe-S (2.8 FADH₂ FAD- Succinate Fumarate https://canvas.uts.edu.au/assessment questions/356986/files/1562694/download? 2e verifier-eUTT3hYal2YYTWlywV8TIFA3USmzCsM52jECmvTo O Succinate is reduced to fumarate O Succinate is oxidised to FAD O The Fe-S center shuffles electrons from FAD to ubiquinone (Q) O The Fe-S center shuffles electrons from FADH2 to ubiquinone (Q) The Fe-S center shuffles electrons from FADH2 to ubiquinonol (QH2) W 88 16°C
22:23 1O 000 · 11:24 A9 OB1 r ll l 52% . +964 782 734 3923 2m541139927815107... Patient Encounter Part 3 The pretreatment workup is summarized below. Pathology: 47-year-old female with new diagnosis of infiltrating intraductal adenocarcinoma involving the left breast and regional node. Further tests on tumor samples indicated ER (8%), PR (negative), HER2 (negative), Ki-67 (72%), and grade (poorly differentiated). Intrinsic subtype (luminal B, HER2-negative). Radiology: FDG-PET/CT indicated a 5.3 x 2.5 cm mass in the left breast which appeared to extend to the epidermis of the skin; one node in the left axilla was also involved with tumor. No other evidence of distant disease was visualized. Laboratory: CBC, liver, and kidney function tests WNL, alkaline phosphatase and calcium are normal also. Stage: IB (T, N, M,) List the most important prognostic factors in this patient with newly diagnosed breast cancer. Assess the patient's level of risk for relapse. 50 SECTION 16 | ONCOLOGIC…
please help me I can't find answers for these questions: here is the link for the article https://www.pbs.org/wgbh/nova/transcripts/2805cancer.html What type of substances are angiostatin and endostatin and where are they produced? What do they do? A) describe the experiments using cow bones to discover anti-angiogenic substances. Why was this used as a source of these potential proteins? B) describe the “accidental” discovery of a novel antiangiogenic substance because of lab contamination?
MM, a 54-year old female presents to the Family Medicine Clinic due to a 2-week history of increasing shortness of breath and cough and mild/moderate pain in left side. She was diagnosed with infiltrating intraductal adenocarcinoma of the left breast 5 years ago; at that time, ER(-)/ PR(-); her-2/neu(+); p53(+); staged as having T3N1M0, stage IIIA, high-risk breast cancer. She underwent a modified radical mastectomy with axillary node dissection followed by 6 cycles of CMF chemotherapy. Her mother and sister also had a history of breast cancer. Past Medical History Gravida 4, para 4; menses onset age 13; HTN x 10 years; Type 2 DM x 8 years; breast CA described above; remained disease free until present follow up. Past Surgical History: Left modified radical mastectomy 5 years ago; cholecystectomy 14 years ago. Medications: Glyburide, 5mg PO BID Verapamil SR, 240mg PO daily Furosemide, 40mg PO daily Allergies: NKDA Physical Examination: GEN: Well-developed, obese woman in no…
What exactly does "DFR" stand for?
Give the letters for the side groups that are likely to interact strongly with blood plasm NH, NH, CH3 NH, H-C-C HN' H-C-C-C-C CH3 H-C-C--C-C A. HN-C NH3 NH, H-C-C-OH H-C-C- -OH H-C-C NH, NH, H-C-C- H-C-C-C-C-C-NH,
A patient being treated for metastatic carcinoma was found to have a white cell count of 5 x 10°/L with 5 metarubricytes (nucleated red cells) per 100 WBCs. What is the corrected white cell count for this patient?
Sequence A: TCT/ TCC/ CTC/ CTA/ AAC/ GTT/ CAA/ CCG/ GTT/ CTT/ AAT/ CCG/ CCG/ CCA/ GGG/ CCC/ CGC/ CCC/ TCA/ GAA/ GTT/ GGT AGA Sequence B: TCA/ GAC/ GTT/ TTT/ GCC/ CCG/ TAA/ CAA/ CTT/ GTT/ ACA/ ACA/ TGG/ TCA/ TAA/ ACG/ TCA/ GAG/ ATG/ GTC/ AAT/ CTC/ TTA/ ATG/ ACT Sequence C: TAT/ ATA/ CAT/ GTA/ AAC/ ACA/ TAC / TCA/ GTG/ GAC/ CAA/ CTC/ AAC/ ATA/ AAC/ CAA/ ACA/ CCG/ CTC/GCG/ CCG/ AAA/ AAG/ ATA/ TGG STEP 1: Transcribe each of the 3 DNA sections into nRNA. Write out the complementary CODONS directly below the DNA strands. STEP 2: Clearly identify the three fragments as the FIRST, SECOND and THIRD fragments by clearly labeling any obvious PROMOTERS, START and STOP codons. STEP 3: Number the the START codon #1 and number the codons in the correct order until the STOP codon is reached. STEP 4: Codons 14- 64 (including 14 & 64) represent an intron. Draw a single red line through these codons to indicate that they will NOT be translated. STEP 4: In the space provided, write out the…